This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Koul, R. Articles by Al-Lamki, Z. Search for Related Content PubMed PubMed Citation Articles by Koul, R. Articles by Al-Lamki, Z. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Guillain-Barre Syndrome Social Bookmarking                   What's this?

Ten-Year Prospective Study (Clinical Spectrum) of Childhood Guillain-Barré Syndrome in the Arabian Peninsula: Comparison of Outcome in Patients in the Pre— and Post—Intravenous Immunoglobulin Eras

Department of Child Health, Sultan Qaboos University Hospital, Al Khod, Sultanate of Oman, roshankoul{at}hotmail.com, rkoul{at}omantel.net.om.

Alexander Chacko, MD, DCH

Department of Child Health, Sultan Qaboos University Hospital, Al Khod, Sultanate of Oman

Riaz Ahmed, MD, DM

Department of Childhealth, Royal Hospital, Ministry of Health, Muscat, Sultanate of Oman

Thomas Varghese, MD, MRCP

Department of Childhealth, Royal Hospital, Ministry of Health, Muscat, Sultanate of Oman

Hashim Javed, MD, MRCPCH

Department of Child Health, Sultan Qaboos University Hospital, Al Khod, Sultanate of Oman

Zakia Al-Lamki, FRCPCH

Department of Child Health, Sultan Qaboos University Hospital, Al Khod, Sultanate of Oman

A prospective study of Guillain-Barré syndrome from January 1992 to December 2001 was undertaken. Intravenous immunoglobulins were used in all patients. All patients were followed up until complete recovery. Various parameters, such as onset of weakness, duration of hospital stay, ventilation requirement, residual deficit, and mortality, were recorded. Acute relapses and fluctuations were also noted. The pattern of this group was compared with patients before 1992, who were not given intravenous immunoglobulins in the Sultanate of Oman. Our data were compared with a few studies prior to 1992 from the medical literature. Our study revealed a definite benefit with intravenous immunoglobulins. The disease course and hospital stay were shortened. Fewer patients needed ventilation. There was no mortality, and the residual deficit was less than 5%. Occasional relapses at a later stage in the course of illness have been noted in acute Guillain-Barré syndrome. However, acute relapse, a new phenomenon that was not seen in the pre—intravenous immunoglobulin era, stood at 11.9%. Intravenous immunoglobulins have made a significant difference in the outcome of Guillain-Barré syndrome, but one has to be aware of acute relapses, which usually occur in the first 2 to 3 weeks after administration. (J Child Neurol 2003;18:767—771).

Journal of Child Neurology, Vol. 18, No. 11, 767-771 (2003)
DOI: 10.1177/08830738030180110501


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. A. Hughes, J. Charlton, R. Latinovic, and M. C. Gulliford No association between immunization and guillain-barre syndrome in the United kingdom, 1992 to 2000. Arch Intern Med, June 26, 2006; 166(12): 1301 - 1304. [Abstract] [Full Text] [PDF]

				F. J. DiMario Jr Intravenous Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial Pediatrics, July 1, 2005; 116(1): 226 - 228. [Full Text] [PDF]